Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.328 EUR | +1.46% | +1.79% | -39.64% |
May. 29 | European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading | MT |
May. 28 | Solaria expects energy prices to rise this year | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.83 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.64% | 6.12B | A- | ||
-2.29% | 89.87B | A- | ||
-3.95% | 37.57B | A- | ||
+63.05% | 26.47B | A | ||
-22.14% | 14.25B | C | ||
-7.96% | 12.99B | B- | ||
-9.33% | 11.93B | D+ | ||
-46.33% | 10.84B | B | ||
+5.77% | 9.11B | B+ | ||
-17.66% | 7.32B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GRF Stock
- Ratings Grifols, S.A.